Study M452
Study name | Kageyama Y 2017b |
Title | Plasma nervonic acid is a potential biomarker for major depressive disorder: a pilot study |
Overall design | The aim of this study was to investigate the use of nonpolar or medium-polar metabolites as biomarkers in plasma samples of drug-free patients with major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ). A comprehensive metabolome analysis of plasma samples from drug-free patients with MDD (depression group, n = 9), BD (n = 6), SZ (n = 17), and matched healthy controls (control group, n = 19) (cohort 1) were performed, using liquid chromatography time-of-flight mass spectrometry. The reproducibility of the results and effects of psychotropic medication on nervonic acid, were verified in cohort 2, an independent sample set of medicated patients [MDD (n = 45), BD (n = 71), SZ (n = 115)], and controls (n = 90) using gas chromatography time-of-flight mass spectrometry. |
Study Type | Type1; |
Data available | https://academic.oup.com/ijnp/advance-article/doi/10.1093/ijnp/pyx089/4356809#supplementary-data |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnoses of depressive disorders |
Sample size | 163 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: not reported; MS-based; GC-MS: 7890A GC (Agilent Technologies, Inc.) with JMS-T100GCV time-of-flight mass spectrometer (JEOL Ltd); |
PMID | |
DOI | |
Citation | Kageyama Y, Kasahara T, Nakamura T, et al. Plasma nervonic acid is a potential biomarker for major depressive disorder: a pilot study. Int J Neuropsychopharmacol 2017;pyx089. |
Metabolite |
